DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA

Lobbying Spend

—

Filings

Firms Hired

Active Period

2022–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	5	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
VENABLE LLP	—	20

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	5
HOUSE OF REPRESENTATIVES	3

Most frequently reported lobbying issues

Issue Code	Description	Reports
Budget/Appropriations	Budget/Appropriations	20
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	5

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 3799117th Congress

PREVENT Pandemics Act

2022 · second_quarter · Firm: VENABLE LLP

Cited source text and reported amounts

Issues related to neglected diseases research and development and access; COVID treatments research and development; S. 3799 - PREVENT Pandemics Act.

Client expense: — · Firm income: $10,000

Matched citations: S. 3799